Fresotig (tigecycline) is a tetracycline derivative (a glycylcycline) for intravenous infusion. In the era of antibiotic resistance, useful antibiotics like meropenem, imipenem are getting resistant due to excessive use. Tigecycline is a promising antibiotic as it has got excellent in vitro activity against ESBLs-producing Enterobacteriaceae and is a potent antibiotic against carbapenem-resistant Enterobacteriaceae.



Each single dose 10ml glass vial of Fresotig contains 50mg of tigecycline as an orange lyophilized powder for reconstitution. 


The recommended dosage regimen is an initial dose of 100 mg, followed by 50 mg every 12 hours. I.V. infusion should be administered over approximately 30 to 60 minutes.
The recommended duration of treatment with tigecycline for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The recommended duration of treatment with tigecycline for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient’s clinical and bacteriological progress.


•    Complicated Skin and Skin Structure Infections
•    Complicated Intra-Abdominal Infections 
•    Community-Acquired Bacterial Pneumonia

Product Information

Each vial contains:
Tigecycline USP 50mg